Novogen begins second human clinical trial of novel compound NV-52 for inflammatory bowel disease

By Lisa Kerner

Charlotte, N.C., Aug. 7 - Novogen Ltd. is starting a second human clinical study of its investigational anti-inflammatory compound, NV-52, following the successful completion of toxicology testing.

NV-52 is a novel compound developed by Novogen to target inflammatory bowel disease, according to a company news release.

In the clinical trial, conducted at the Pacific Private Hospital in Brisbane, Queensland, 12 volunteers will receive NV-52 administered in a repeat dose over seven days.

Novogen is studying the drug's use on a long-term basis and testing NV-52's ability to change certain inflammatory markers.

Inflammatory bowel disease, including ulcerative colitis and Crohn's disease, affects about 1 in 1,000 individuals. In addition to causing pain, diarrhea, rectal bleeding, weight loss and fatigue, inflammatory bowel disease has about an 80% recurrence rate.

"If the efficacy in humans is similar to that already observed in mice, this new drug will have the potential to offer new therapeutic opportunities in this difficult disease indication," study director Laurie Howes said in the news release.

Novogen is a biotechnology company based in Sydney, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.